Trial Profile
A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CGC
- 05 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Apr 2028.
- 05 Feb 2024 Planned primary completion date changed from 1 Jun 2022 to 1 Apr 2026.
- 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.